With FDA approval, anti-PD-1 antibodies became the first-line treatment for advanced melanoma over ipilimumab, dacarbazine, and high-dose IL-2 due to their superior response rates, durability, and lower rates of systemic toxicity. Here, IL2 is linked to melanoma.